MedTrace Logo

Sorafenib Combined With Venetoclax as Pre-emptive Therapy Strategy for MRD+ AML: a Prospective, Single-arm, Multicenter Clinical Study

NCT07264010 · Status: NOT_YET_RECRUITING · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 87

Last updated 2025-12-04

No results posted yet for this study

Summary

The purpose of this study is to explore the efficacy and safety of sorafenib combined with venetoclax as pre-emptive therapy strategy for measurable residual disease persisting acute myeloid leukemia.

Conditions

  • Acute Myeloid Leukaemia (AML)
  • Measurable Residual Disease (MRD)

Interventions

DRUG

Sorafenib (SORA)

Sorafenib (SORA) was administered at 400mg twice daily on days 1 to 28.

DRUG

Venetoclax (VEN)

Venetoclax (VEN) was administered at 400mg/day on days 1 to 28.

Sponsors & Collaborators

  • Nanfang Hospital, Southern Medical University

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-12-01
Primary Completion
2026-12-30
Completion
2028-12-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07264010 on ClinicalTrials.gov